Home >> Marketplace Archives >> Beckman joins forces with Johns Hopkins

Beckman joins forces with Johns Hopkins

Print Friendly, PDF & Email

November 2018—Beckman Coulter Diagnostics is collaborating with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in health care.

Beckman Coulter will observe Johns Hopkins’ researchers and clinicians as they work to develop new technologies and concepts, potentially leading to medical breakthroughs that could help patients. Beckman will be able to test solutions on site with experts who are working toward better patient care. These solutions may be brought to market and contribute to elevating health care.

“It is critical to explore and test new and innovative solutions with clinicians working in actual clinical settings to determine real-world quality and effectiveness. This will help us to address clinical challenges in a rapidly changing environment and foster our efforts to move health care forward for every person,” John Blackwood, Sr. VP and general manager of products and services, Beckman Coulter Diagnostics, said in a press release.

Beckman Coulter Diagnostics, 714-993-5321


Check Also

Beckman Coulter adds 6-AM and BUP assays, 4/18

April 2018—Beckman Coulter Diagnostics announced the addition of 6-acetylmorphine and buprenorphine assays to its menu of drugs-of-abuse tests for use on its AU chemistry analyzers (AU480, AU680, AU5800). The Syva Emit II Plus 6-AM assay provides a convenient and quick way to selectively screen for heroin use, in place of methods such as gas chromatography and mass spectrometry.